These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Li X; Fujio M; Imamura M; Wu D; Vasan S; Wong CH; Ho DD; Tsuji M Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13010-5. PubMed ID: 20616071 [TBL] [Abstract][Full Text] [Related]
4. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Wu L; Gabriel CL; Parekh VV; Van Kaer L Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798 [TBL] [Abstract][Full Text] [Related]
5. The role of invariant NKT cells at the interface of innate and adaptive immunity. Cerundolo V; Kronenberg M Semin Immunol; 2010 Apr; 22(2):59-60. PubMed ID: 20172739 [No Abstract] [Full Text] [Related]
6. Glycolipid activators of invariant NKT cells as vaccine adjuvants. Kharkwal SS; Arora P; Porcelli SA Immunogenetics; 2016 Aug; 68(8):597-610. PubMed ID: 27377623 [TBL] [Abstract][Full Text] [Related]
7. NKT-cell help to B lymphocytes can occur independently of cognate interaction. Tonti E; Galli G; Malzone C; Abrignani S; Casorati G; Dellabona P Blood; 2009 Jan; 113(2):370-6. PubMed ID: 18832653 [TBL] [Abstract][Full Text] [Related]
8. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy. Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371 [TBL] [Abstract][Full Text] [Related]
9. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy. Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790 [TBL] [Abstract][Full Text] [Related]
10. The ins and outs of type I iNKT cell development. Shissler SC; Webb TJ Mol Immunol; 2019 Jan; 105():116-130. PubMed ID: 30502719 [TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship studies of novel glycosphingolipids that stimulate natural killer T-cells. Tashiro T Biosci Biotechnol Biochem; 2012; 76(6):1055-67. PubMed ID: 22790924 [TBL] [Abstract][Full Text] [Related]
12. Harnessing CD1d-restricted T cells toward antitumor immunity in humans. Neparidze N; Dhodapkar MV Ann N Y Acad Sci; 2009 Sep; 1174():61-7. PubMed ID: 19769737 [TBL] [Abstract][Full Text] [Related]
13. Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity. Chennamadhavuni D; Saavedra-Avila NA; Carreño LJ; Guberman-Pfeffer MJ; Arora P; Yongqing T; Pryce R; Koay HF; Godfrey DI; Keshipeddy S; Richardson SK; Sundararaj S; Lo JH; Wen X; Gascón JA; Yuan W; Rossjohn J; Le Nours J; Porcelli SA; Howell AR Cell Chem Biol; 2018 May; 25(5):571-584.e8. PubMed ID: 29576533 [TBL] [Abstract][Full Text] [Related]
14. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide. Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160 [TBL] [Abstract][Full Text] [Related]
15. Structural basis for the recognition of C20:2-αGalCer by the invariant natural killer T cell receptor-like antibody L363. Yu ED; Girardi E; Wang J; Mac TT; Yu KO; Van Calenbergh S; Porcelli SA; Zajonc DM J Biol Chem; 2012 Jan; 287(2):1269-78. PubMed ID: 22110136 [TBL] [Abstract][Full Text] [Related]
16. Human invariant NKT cell subsets differentially promote differentiation, antibody production, and T cell stimulation by B cells in vitro. Zeng SG; Ghnewa YG; O'Reilly VP; Lyons VG; Atzberger A; Hogan AE; Exley MA; Doherty DG J Immunol; 2013 Aug; 191(4):1666-76. PubMed ID: 23851681 [TBL] [Abstract][Full Text] [Related]
17. Structural determination of lipid antigens captured at the CD1d-T-cell receptor interface. Brennan PJ; Cheng TY; Pellicci DG; Watts GFM; Veerapen N; Young DC; Rossjohn J; Besra GS; Godfrey DI; Brenner MB; Moody DB Proc Natl Acad Sci U S A; 2017 Aug; 114(31):8348-8353. PubMed ID: 28716901 [TBL] [Abstract][Full Text] [Related]
18. Application of natural killer T cells in antitumor immunotherapy. Hong C; Park SH Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797 [TBL] [Abstract][Full Text] [Related]
19. Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines. Lameris R; Schneiders FL; de Gruijl TD; van der Vliet HJ Methods Mol Biol; 2014; 1139():155-65. PubMed ID: 24619678 [TBL] [Abstract][Full Text] [Related]
20. Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells. Silk JD; Salio M; Reddy BG; Shepherd D; Gileadi U; Brown J; Masri SH; Polzella P; Ritter G; Besra GS; Jones EY; Schmidt RR; Cerundolo V J Immunol; 2008 May; 180(10):6452-6. PubMed ID: 18453560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]